Artiva Biotherapeutics, Inc. (ARTV)
D
Pipeline Grade
Financial Position (from SEC Filings)
$21.4M
Cash & Equivalents
$21.0M
Quarterly Burn Rate
3 mo
Est. Cash Runway
$468M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-07-01 | Phase1 Readout | — |
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06991114 | AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Stu... | PHASE2 | Recruiting | 90 |
| NCT06581562 | Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associate... | PHASE1 | Recruiting | 30 |
| NCT06265220 | AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or ... | PHASE1 | Active Not Recruiting | 51 |
| NCT06699771 | Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies | PHASE1 | Recruiting | 48 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.